Orr v. Elyea

279 F.R.D. 474, 2009 U.S. Dist. LEXIS 106574, 2009 WL 3837553
CourtDistrict Court, C.D. Illinois
DecidedNovember 16, 2009
DocketNo. 08-CV-2232
StatusPublished
Cited by2 cases

This text of 279 F.R.D. 474 (Orr v. Elyea) is published on Counsel Stack Legal Research, covering District Court, C.D. Illinois primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Orr v. Elyea, 279 F.R.D. 474, 2009 U.S. Dist. LEXIS 106574, 2009 WL 3837553 (C.D. Ill. 2009).

Opinion

OPINION

MICHAEL P. McCUSKEY, Chief Judge.

On April 5, 2009, Plaintiffs filed an Amended Motion to Certify Class (#47). Defendant Wexford Corporation filed its Response (# 61) on May 1, 2009. Defendants Willard O. Elyea and Michael Puisis filed their Response (# 76) on June 22, 2009. For the following reasons, Plaintiffs’ Amended Motion to Certify Class (#47) is DENIED.

BACKGROUND

Plaintiffs’ Motion

In its Amended Motion to Certify Class (# 47), Plaintiffs note that all of the current Plaintiffs are either residents or former residents of the Illinois Department of Corrections (IDOC) and have each been diagnosed with Hepatitis C and have elevated liver enzymes. Plaintiffs identify the class as IDOC inmates who at some point during their incarceration had Hepatitis C and elevated liver enzymes but received no Hepatitis C treatment. However, Plaintiffs then go on to break down the class into four subgroups: (1) former residents who have been released but did not receive treatment while incarcerated; (2) those residents with a genotype susceptible to treatment within 12 weeks and who have more than 12 weeks to stay; (3) those residents with genotypes requiring 48 week treatment with more than 48 weeks remaining on their sentence but who are not receiving treatment; and finally (4) those with a genotype indicating a 48 week treatment who have less than 48 weeks remaining on their period of incarceration. Plaintiffs also claim there could possibly be another subgroup of persons of either genotype who have been diagnosed within 12 weeks of their release date.

Plaintiffs then discuss the statutory requirements for class certification. Plaintiffs claim “[t]he class is numerous in that it represents something in excess of 2000 individuals and because of the identity issues notified above, it is not practical for the Plaintiffs or counsel to contact each of those individuals and request that they join in individual suit.” Plaintiffs claim that there are identical issues of fact and law as to each of the Plaintiffs: a resident of the IDOC with Hepatitis C. The issues will be identical among the individuals in the various “sub-classes” and among the class as an entire “entity.”

Plaintiffs contend that the ability to maintain the class is strong because the position of the Defendants is the same to each and every Plaintiff, thus making a final ruling applicable to all. Notice is met because the majority of the Plaintiffs are in Defendants’ custody and many of those out of custody are still under mandatory supervised release. Kent Heller will act as Plaintiffs’ class counsel.

Defendants’ Response

Defendants argue that Plaintiffs have not established the prerequisites for maintaining a class under Rule 23:

(1) Commonality—Defendants believe Plaintiffs have framed the issue too broadly, [476]*476as not all of the inmates will have less than one year remaining on their sentence and not all the inmates will be candidates for Hepatitis C treatment.

(2) Typicality—Every Plaintiffs’ individual circumstances are going to be different in terms of their particular genotype, length of sentence, whether they are candidates for treatment in the first place, whether they were offered treatment, whether they refused treatment, and whether there is a gap in incarceration.

(3) Adequacy—No specific class representatives have been named. No affidavits or other evidence has been provided to demonstrate that any of the named Plaintiffs fit into the class or subclasses set forth in the motion. It is unknown which of the Plaintiffs were affected by the policy, what their treatment regimen was, and the nature of their alleged Hepatitis C. Plaintiffs counter, however, that the IDOC medical department will not release the records to them out of privacy concerns. Defendants also point out that, of the 165 Plaintiffs, 56 are no longer incarcerated, making it difficult to conceive how they could adequately represent the Rule 23(b)(2) class seeking injunctive relief as their release from incarceration renders such claims moot.

(4) Questions of Law and Fact—Defendants argue that the question of deliberate indifference under the Eighth Amendment is a ease-by-case fact specific problem. Defendants would also have the court take notice of Judge Harold A. Baker’s decision in Roe v. Sims, 06-CV-3034, where he denied class status for many of the same reasons advanced by Defendants.

Judge Baker’s Ruling in Roe v. Sims, 06-CV-3034.

In Roe v. Sims, 06-CV-3034, four plaintiffs with Hepatitis C sued Defendant Elyea in this court over the same IDOC treatment policy at issue in this case. Plaintiffs in that case filed a motion to certify, saying, again, “[t]he Class can easily be described as those inmates within the Department of Corrections who at some point in time during their incarceration had Hepatitis C and elevated liver enzyme levels but received no treatment for that Hepatitis.”

Judge Baker denied the motion for class certification, writing:

“However, as the Guidelines demonstrate, determining the appropriate treatment for an inmate with Hepatitis C is not easily described or determined. It seems to the court on the current record that inmates’ experience with Hepatitis vary widely. Elevated liver enzymes are only one factor in the determination of whether a liver biopsy should be performed, and many different factors affect whether drug therapy should be initiated. History and physicals, as well as other clinical and lab tests are important, along with determining the existence of contraindications. Here, the Court cannot even tell if Plaintiffs were viable candidates for drug therapy treatment, be it 12, 24 or 48 week[s].
In sum, the record does not support Plaintiffs’ assertion that ‘the position of the Defendant is identical to each and every Plaintiff ...” ..., or that the questions of law and fact share enough commonality and typicality for class certification, at least on the present record. Nor have Plaintiffs demonstrated that they adequately represent the class of inmates aggrieved by Dr. Elyea’s policy. Plaintiffs do not even offer their own expert testimony about what their condition is or what care they received in prison. Accordingly, the Court is not persuaded that class certification is appropriate.”

ANALYSIS

The Seventh Circuit has recently confirmed that district courts should exercise “caution in class certification generally.” Thorogood v. Sears, Roebuck & Co., 547 F.3d 742, 746 (7th Cir.2008). A plaintiff seeking class certification has the burden of proving that the proposed class meets the requirements of Rule 23. Herkert v. MRC Receivables Corp., 254 F.R.D. 344, 347 (N.D.Ill. 2008), citing Williams v. Chartwell Fin. Servs., Ltd., 204 F.3d 748, 760 (7th Cir.2000). Failure to meet any of the requirements of Rule 23(a) precludes class certification. Herkert, 254 F.R.D. at 347, citing Oshana v. Coca-Cola Co., 472 F.3d 506, 513 (7th Cir.[477]*4772006). Further, the potential class must also satisfy at least one provision of Rule 23(b).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Rose v. Sandy
S.D. West Virginia, 2025
Kress v. CCA of Tennessee, LLC
272 F.R.D. 222 (S.D. Indiana, 2010)

Cite This Page — Counsel Stack

Bluebook (online)
279 F.R.D. 474, 2009 U.S. Dist. LEXIS 106574, 2009 WL 3837553, Counsel Stack Legal Research, https://law.counselstack.com/opinion/orr-v-elyea-ilcd-2009.